Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Serrapeptase and Improved Mucociliary Transportability

Doses used in studies

mg/day: 30 (median 30, IQR 30–30) — 1 study

Time to effect

Median: 4 weeks · IQR 4 weeks–4 weeks · Range 4 weeks–4 weeks — Reported in 1 of 1 study

1 of 1 paper

Effect of the proteolytic enzyme serrapeptase in patients with chronic airway disease.
- 2003-08-07
- RCT · n = 15
- Respirology (Carlton, Vic.) 8(3)
- - Seiichi Nakamura
  - Yasushi Hashimoto
  - Masashi Mikami
  - Eiichi Yamanaka
  - Tomoyuki Soma
  - Mitsunori Hino
  - Arata Azuma
  - Shoji Kudoh
- PubMed: 12911824
- DOI: 10.1046/j.1440-1843.2003.00482.x
8 Insights on
- Improved Mucociliary Transportability
- High evidence
- Clinical
The mean mucociliary transportability index increased from 13.3 +/- 1.8 to 24.4 +/- 2.5 (P = 0.0103).
Effect
Beneficial
Effect size
Large
Significant
Yes
Dose
30 mg/day